Freyherr Intnl Group - Issue of Equity
RNS Number : 9865S
Freyherr International Group PLC
11 November 2019

Freyherr International Group plc


Issue of Equity

The Directors of Freyherr International Group plc ('Freyherr International' or 'the Company'), the medicinal cannabis group based in Slovenia, are pleased to announce that they have decided to accept a limited number of subscriptions for Ordinary Shares where funds have been received by the Company after the Company's Admission to trading.


In total the Board have issued 19,633 new ordinary shares at 170p per share to new and existing shareholders for cash and the capitalisation of historic loan interest.


Following these share issues, completed on 6 November, the issued share capital of the Company is now 25,783,501 ordinary shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

The Board is aware of the recent trade in the Company's shares at a price substantially below the market price.  The Company knows of no reason connected to the Company that would justify such a decline.  The Company continues to perform in line with management expectations.

The directors of the issuer accept responsibility for the contents of this announcement

For further information please contact:




Tomaž Frelih

Freyherr International Group plc

No.1 London Bridge

London SE1 9BG





00 386 (41) 444 845


Corporate Advisor

David Papworth

Level 17 Dashwood House

69 Old Broad Street





0207 101 7676


Investor Relations

Tony Burke

97 Jermyn Street





020 7839 5081


Note to Editors:

Freyherr International Group plc is the UK parent company of a group engaged in the production and sale of medicinal cannabis, cannabis cultivation and the production of cannabis dosing and dispensing packaging. Operations are centred in Slovenia and the Group principally operates within the EU.


The Group currently consists of 3 operating companies:


Freyherr d.o.o. has expertise in the cultivation and harvesting of cannabis as well as the formulation, marketing and distribution of cannabis and cannabis derived concentrates and extracts. It is currently growing cannabis in Slovenia and has invested in various cannabis production facilities in other jurisdictions.


Freyherr Pharma d.o.o. is the analytics and pharmaceutical arm of the Group and holds an EU GMP certificate. It operates from its own certified building and manufactures CBD products for the Group and produces white label CBD products supplying them to various EU countries;


Patron d.o.o. is the dosing and dispensing arm which has been trading since 2015 it markets products suitable for dispensing concentrates and extracts of all sorts of nutritional and pharmaceutical products.  The company also offers Cannabinoid analysis to identify the h THC, CBD, or CBN levels in a given extract, concentrate or plant;

This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit